HR0103 103RD GENERAL ASSEMBLY

HR0103 LRB103 31109 MST 57773 r

HOUSE RESOLUTION

WHEREAS, The substance use and opioid use crises in Illinois are responsible for historically high rates of overdoses and overdose-related fatalities; and

WHEREAS, According to the State's own opioid data, use and misuse of opioids in Illinois also continues to have substantial associated public health consequences, including increased rates of infectious diseases such as hepatitis C and HIV, lost productivity in the workplace, crime, neonatal abstinence syndrome, and homelessness; and

WHEREAS, Substance use and opioid use are often detrimental to a person's mental health; access to innovative and evidence-based treatments that address substance use and opioid use can improve a patient's overall mental health; and

WHEREAS, Historically disadvantaged groups face additional barriers to treatment for substance use and opioid use disorders, such as a lack of affordable therapy, stigma, and unequal access to mental health treatment; mental health equity should focus on access to quality and appropriate healthcare services; and

WHEREAS, The purpose of many federal programs is to provide resources to states for increasing access to FDA-approved medications for the treatment of substance use and opioid use disorder and for supporting the continuum of prevention, harm reduction, treatment, and recovery support services for opioid use disorder and other substance use disorders; and

WHEREAS, A prescription digital therapeutic, which utilizes both cognitive behavioral therapy and contingency management in the product to treat substance use disorder or opioid use disorder, is approved, cleared, or classified by the Food and Drug Administration under section 510(k), 513(f), or 515 of the Federal Food, Drug, and Cosmetic Act and requires a prescription under section 801.109 of title 21 of the Code of Federal Regulations (or any successor regulation); and

WHEREAS, Prescription digital therapeutics have the potential to significantly improve health care delivery to underserved populations because they transcend care access limitations due to geography, socioeconomic status, trust of traditional institutions, and more; and

WHEREAS, Clinical studies have shown significantly greater odds of stimulant and opioid abstinence during treatment if treatment as usual is combined with an FDA-authorized PDT that has both cognitive behavioral therapy and contingency management; and

WHEREAS, A 2018 study demonstrated that when a Community Reinforcement Approach and Contingency Management are administered together then a patient is 2.84 times more likely to remain abstinent at the end of the treatment than those in other programs; and

WHEREAS, The White House's Office of National Drug Control Policy recently released its 2022 National Drug Control Strategy document; specifically, the document points to prescription digital therapeutics and how these tools could help increase services for a wide array of patients; and

WHEREAS, Federally-funded programs help many states to fund access to FDA-authorized PDTs for patients and providers; therefore, be it

RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we urge the Department of Human Services and the Governor's Opioid Overdose Prevention and Recovery Steering Committee to closely consider funding FDA-authorized PDTs to help patients who are struggling with substance use and opioid use disorders; and be it further

RESOLVED, That a suitable copy of this resolution be delivered to the Secretary of the Illinois Department of Human Services.